Current Affairs - Technology

Exercise : Technology - Latest Current Affairs
  • Technology - Latest Current Affairs
61.
Which institution developed AI-based antibiotics to combat drug-resistant infections like MRSA and Neisseria gonorrhoeae?
Stanford University
Oxford University
Massachusetts Institute of Technology
Harvard University
Answer: Option
Explanation:
Researchers at the Massachusetts Institute of Technology (MIT) have successfully developed two potential antibiotics using generative AI to address the growing challenge of drug-resistant infections. These antibiotics are specifically designed to target Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, and methicillin-resistant Staphylococcus aureus (MRSA), a leading cause of hospital-acquired infections. The application of AI in drug discovery accelerates the identification of effective compounds, reducing the time and cost involved in traditional research. This breakthrough represents a significant advancement in the fight against antimicrobial resistance, offering hope for novel treatments against some of the most dangerous superbugs threatening global health.

62.
What is the name of the newly launched portal aimed at simplifying the registration process for newspapers and periodicals?
Media Mitra portal
News Ease portal
Samachar Setu portal
Press Sewa portal
Answer: Option
Explanation:
The Press Sewa portal was launched by the Press Registrar General of India (PRGI) to simplify and streamline the registration process for newspapers and periodicals. This initiative focuses on enhancing transparency, reducing delays in approvals, and improving the overall ease of doing business for publishers. Additionally, sessions like Vartalap, organised by PIB Hyderabad, were conducted to address publishers’ queries and provide them with clear guidance. By adopting digital solutions like Press Sewa, the government aims to modernise the media regulatory framework, ensuring efficient service delivery and strengthening trust between regulatory authorities and publishers.

63.
Which planet is the target of Russia’s planned Venera-D mission scheduled for launch between 2034–2036?
Mars
Jupiter
Saturn
Venus
Answer: Option
Explanation:
Russia’s upcoming Venera-D mission is focused on exploring Venus, one of the most challenging planets to study due to its extreme surface conditions. Planned for launch between 2034 and 2036, the mission will be developed with contributions from the Space Research Institute (IKI) and Lavochkin Association. It is designed to carry advanced scientific instruments, including an orbiter, a lander, and a balloon probe, to conduct comprehensive research on the planet’s atmosphere and surface. This mission represents Russia’s renewed interest in planetary exploration and builds on its historic legacy of Venus missions during the Soviet era.

64.
By which year does NASA plan to build a nuclear reactor on the Moon?
2028
2030
2032
2035
Answer: Option
Explanation:
NASA has accelerated its plans to establish a sustainable human presence on the Moon by aiming to build a nuclear reactor by 2030. The project is central to ensuring a steady and reliable power supply for future lunar bases, critical for both human survival and technological operations. The reactor is expected to generate 100 kilowatts, which, though modest compared to onshore wind turbines, will be sufficient for lunar conditions. This timeline underscores NASA’s long-term strategy for lunar colonization, while also positioning the United States ahead in the global competition, as China and Russia plan similar stations by 2035.

65.
Which institution’s researchers developed Compound 3b to restore the effectiveness of Meropenem against drug-resistant bacteria?
IISc Bengaluru
IIT Roorkee
AIIMS New Delhi
JNU New Delhi
Answer: Option
Explanation:
IIT Roorkee researchers have developed Compound 3b, a significant breakthrough in the fight against antibiotic resistance. This compound works to restore the potency of Meropenem, a commonly used antibiotic, against drug-resistant bacteria such as KPC-2-producing Klebsiella pneumoniae. These pathogens are among the top global health threats identified by the WHO, as they can withstand existing treatments, leading to severe and untreatable infections. By countering this resistance, Compound 3b opens new avenues for effective medical treatment against superbugs. The development underscores IIT Roorkee’s growing contribution to advanced medical and pharmaceutical research aimed at addressing global healthcare challenges.